Rastegar J, Hu A, Chung L, Stevens L, Dixon SW, Schwab P, Ellis JJ. HIV preexposure prophylaxis treatment patterns in a national health plan population. J Manag Care Spec Pharm. 2023 Dec;29(12):1267-74. doi: 10.18553/jmcp.2023.29.12.1267
Asante K, Racsa P, Bloomfield A, Cornett D, Schwab P. Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi. J Manag Care Spec Pharm. 2023 Oct;29(10):1109-18. doi: 10.18553/jmcp.2023.29.10.1109
Bakri SJ, Bektas M, Sharp D, Luo R, Sarda SP, Khan S. Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system. J Manag Care Spec Pharm. 2023 May;29(5-a Suppl):S2-S11. doi: 10.18553/jmcp.2023.29.5-a.s2
Ronquest NA, Paret K, Gould I, Barnett CL, Mladsi (she/her) DM. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports. J Manag Care Spec Pharm. 2021 Nov;27(11):1601-12. doi: 10.18553/jmcp.2021.27.11.1601
Appukkuttan S, Farej R, Miles L, Purser M, Wen L. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2021 Feb;27(2):166-74. doi: 10.18553/jmcp.2020.20330
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S14-20. doi: 10.18553/jmcp.2020.26.12-b.s14
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S8-S14. doi: 10.18553/jmcp.2020.26.12-b.s8
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S3-8. doi: 10.18553/jmcp.2020.26.12-b.s3
Patterson BJ, Herring WL, van Oorschot D, Curran D, Carrico J, Zhang Y, Ackerson BK, Bruxvoort K, Sy LS, Tseng HF. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. J Manag Care Spec Pharm. 2020 Dec;26(12):1567-75. doi: 10.18553/jmcp.2020.20251
Bhattacharya R, Herren K, Poonawalla I, Bunniran S, Bloomfield A, Schwab PE. Comparing medical utilization and cost outcomes in oral versus injectable immunotherapy users with chronic inflammatory joint and skin diseases. J Manag Care Spec Pharm. 2020 Oct;26(10):1246-56. doi: 10.18553/jmcp.2020.26.10.1246
Ferries E, Dye JT, Hall B, Ndehi L, Schwab P, Vaccaro J. Comparison of medication therapy management services and their effects on health care utilization and medication adherence. J Manag Care Spec Pharm. 2019 Jun;25(6):688-95. doi: 10.18553/jmcp.2019.25.6.688
Schwab P, Racsa P, Rascati K, Mourer M, Meah Y, Worley K. A retrospective database study comparing diabetes-related medication adherence and health outcomes for mail-order versus community pharmacy. J Manag Care Spec Pharm. 2019 Mar;25(3):332-40. doi: 10.18553/jmcp.2019.25.3.332
Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States: a post hoc analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul;24(7):617-22. doi: 10.18553/jmcp.2018.24.7.617
Graham J, Earnshaw S, Burslem K, Lim J. Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. health plan. J Manag Care Spec Pharm. 2018 Jun;24(6):544-53. doi: 10.18553/jmcp.2018.24.6.544
Douglas AG, Schwab P, Lane D, Kennedy K, Slabaugh SL, Bowe A. A comparison of brand and biosimilar granulocyte-colony stimulating factors for prophylaxis of chemotherapy-induced febrile neutropenia. J Manag Care Spec Pharm. 2017 Dec;23(12):1221-6. doi: 10.18553/jmcp.2017.23.12.1221
Brogan AP, DeMuro C, Barrett AM, D’Alessio D, Bal V, Hogue SL. Payer perspectives on patient-reported outcomes in health care decision making: oncology examples. J Manag Care Spec Pharm. 2017 Feb;23(2):124-34. doi: 10.18553/jmcp.2017.23.2.125.
Parikh RC, Du XL, Robert MO, Lairson DR. Cost-effectiveness of treatment sequences of chemotherapies and targeted biologics for elderly metastatic colorectal cancer patients. J Manag Care Spec Pharm. 2017 Jan;23(1):64-73. doi: 10.18553/jmcp.2017.23.1.64
Graham J, Mauskopf J, Kawai K, Johnson KD, Xu R, Acosta CJ. Budget-impact analysis of alternative herpes zoster vaccine strategies: a U.S. HMO perspective. J Manag Care Spec Pharm. 2016 Jul;22(7):872-88. doi: 10.18553/jmcp.2016.22.7.872
Yu S, Schwab P, Bian B, Radican L, Tunceli K. Use of add-on treatment to Metformin monotherapy for patients with type 2 Diabetes and suboptimal glycemic control: a U.S. database study. J Manag Care Spec Pharm. 2016 Mar;22(3):272-80. doi: 10.18553/jmcp.2016.22.3.272
Candrilli SD, Meyers JL, Boye K, Bae JP. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities. J Diabetes Complications. 2015 May;29(4):529-33. doi: 10.1016/j.jdiacomp.2014.12.009
Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP. Can we rely on the Dermatology Life Quality Index (DLQI) as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol. 2012 Jan;132(1):76-84. doi: 10.1038/jid.2011.238
Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications. 2007 Oct 1;21(5):306-14.
Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-16.
Nijsten T, Whalley D, Gelfand J, Margolis D, McKenna SP, Stern RS. The psychometric properties of the psoriasis disability index in United States patients. J Invest Dermatol. 2005 Oct 1;125(4):665-72.